J&J's Ottava Clears the FDA: What a New Robotic Platform Means for Surgical Practice

View book at CLNZ Books →

On July 22, 2026, the FDA granted Johnson & Johnson's OTTAVA Robotic Surgical System De Novo authorization for ten upper-abdominal general surgery procedures, including gastric bypass, gastrectomy, cholecystectomy, appendectomy, and hiatal hernia repair. It is the first table-integrated soft-tissue robotic platform to reach the U.S. market and the first genuine regulatory challenger to Intuitive Surgical's two-and-a-half-decade hold on the category — though Intuitive's installed base of 11,710 da Vinci systems, growing 12% year over year, dwarfs OTTAVA's current base of zero. The clearance also establishes a new device classification that may open a regulatory pathway for future table-integrated entrants.

Advancements in Laparoscopy and Robotic Surgery, this quarter's issue of Surgical Clinics (Meara & Duke, eds., Elsevier), was commissioned for exactly this moment. Its second chapter, on integrating artificial intelligence and technology into surgical practice, and its coverage of foregut, bariatric, and colorectal technique, give surgical departments a peer-reviewed reference for evaluating what a multi-platform robotic landscape means for procedure selection, training, and OR workflow — rather than relying on vendor literature alone.

Three uses stand out as departments respond to a widening field of robotic platforms. First, surgical chairs and OR committees comparing platforms for upcoming capital purchases can use Chapter 2's technology-integration review as independent context alongside vendor demonstrations. Second, bariatric and foregut surgery teams — among the first procedure categories OTTAVA was cleared for — can cross-reference Chapters 5 and 6 on foregut innovation and bariatric complication management when evaluating a new platform's procedure fit. Third, residency and fellowship programs can use the full issue as a current teaching reference for trainees who will increasingly encounter more than one robotic system during training.

For surgical department and academic medical libraries, this issue is a compact way to keep a collection current through a period of real platform change, without waiting for the next full textbook edition to catch up with a fast-moving regulatory and competitive landscape.

CLNZ Books sources this title directly from Elsevier, ships worldwide with secure card and PayPal payment, and offers institutional invoicing for library and departmental orders — the same sourcing and support behind every title in our Medicine collection.

Order Now

Q&A

What did the FDA clear for robotic surgery in July 2026?
J&J's OTTAVA Robotic Surgical System received De Novo authorization for ten upper-abdominal general surgery procedures, including gastric bypass, gastrectomy, cholecystectomy, appendectomy, and hiatal hernia repair — the first table-integrated soft-tissue robotic platform cleared in the U.S.

Does this book cover the new wave of competing robotic platforms?
Yes. Chapter 2 is dedicated to integrating artificial intelligence and technology into surgical practice, giving departments a peer-reviewed reference point as more robotic platforms enter the market.

What procedures does Ottava's clearance cover, and does the book address those specialties?
Ottava is currently cleared for upper-abdominal procedures such as gastric bypass and gastrectomy; the book's Chapter 5 (foregut surgery) and Chapter 6 (bariatric surgery) cover the clinical and technical considerations in exactly those areas.

Is this issue useful for surgical training programs?
Yes. Its eleven practice-oriented reviews make it a current teaching reference for residents and fellows who will train across more than one robotic platform as the field diversifies.

Where can I buy Advancements in Laparoscopy and Robotic Surgery?
You can order it directly from CLNZ Books, with worldwide shipping included and secure payment via credit card or PayPal.

Back to blog

Leave a comment